clinical trial · NCT07219212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Johnson & Johnson Enterprise Innovation Inc.·phase1·recruiting·n = 30
Squamous Cell Carcinoma of Head and NeckJNJ-90301900CisplatinIntensity Modulated Radiation Therapy (IMRT)
brief summary
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
started
Jan 26, 2026
primary completion
Jul 14, 2028
completion
Jul 14, 2028
last updated
Apr 13, 2026
official title
A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol